<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220304054179N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-13</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The efficacy of an iranian traditional herbal compound in treatment of dyspepsia</public_title>
      <acronym></acronym>
      <scientific_title>Study the efficacy of an iranian traditional herbal compound in treatment of functional dyspepsia, add-on double blind randomized controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-03-12</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>150</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62308</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study is an add-on double blind randomized controlled trial study, and only statisticians know which code is drug or placebo and the questioner and patient are blinded. randomized allocation is done using block randomization; In blocking, variables such as age and sex and routine drug use and severity of symptoms will be considered. Random Sequence generation will also be done using Randomizer software.
After the patient enters, the necessary explanations about the plan are provided to him and then his consent is received in the form of consent and his registration is done, based on the variables related to blocking (such as age, sex and routine medication) He is assigned, and from the codes in that block, a code is randomly assigned to the patient and the sachet with that code is delivered to the patient, Blinding description: Participants &amp; Questioner are blinded by the end of the project.
The pharmacologist is aware of the contents of the sachets (drug or placebo).
The statistician who prepares the blocks and tables of random numbers is aware of the content of the codes (drug or placebo).</study_design>
      <phase>3</phase>
      <hc_freetext>Dyspepsia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: This group receives the drug, which contains a traditional herbal composition. the components of the product include the seeds of the anise plant and the seeds of the fennel plant and the seeds of the Trachyspermum plant and the seeds of the caraway plant, which are grinded and placed in 8-gram sachets by traditional medicine pharmacist in the drug manufacturing center located in Emam Reza Clinic. Each patient is given 28 sachets. The method of taking the medicine is one sachet in the morning before breakfast and one sachet at night at bedtime, which is consumed with half a glass of water, and the treatment period is two weeks. Intervention 2: Control group: The group that receives placebo. The placebo includes corn starch, wheat bran and barley flakes and 10% of the herbal composition of the drug (to simulate the appearance of the drug), which is prepared by a traditional medicine pharmacist in the drug manufacturing center located in Emam Reza Clinic in Shiraz and placed in 8 gram sachets.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after unidentifiable individuals.

When:
Access period starts 6 months after the results are published.

To whom:
All researchers can apply for data or other study documentation.

Conditions:
Any use of the data, analysis or copying must be done with the permission of the researcher and with respect to his intellectual rights.

Where to obtain:
Soodabeh Samimi, 09177921159, samimisoodabeh@sums.ac.ir

How to obtain:
The review and response to the applicant will take a maximum of one month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Soodabeh Samimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand Ave., School of Medicine, 7th Floor, Department of Iranian Traditional Medicine</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۳۳۶ - ۷۱۳۴۸</zip>
        <telephone>۳۲۳۴۵۱۴۵-۰۷۱</telephone>
        <email>samimisoodabeh@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Majid Nimroozi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand Ave.</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۳۳۶ - ۷۱۳۴۸</zip>
        <telephone>۳۲۳۴۵۱۴۵-۰۷۱</telephone>
        <email>mnimruzi@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18-65 years old
Men and women
Patients with one of the symptoms of ROME4 dyspepsia.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Dyspepsia with organic causes
Pregnant women,  having plan to conceive through the study duration
Lactating women
Positive history of chronic liver diseases, renal diseases, diabetes and malignancies
Taking anticoagulants including warfarin, Plavix, aspirin and other chemical agents, and herbal remedies that may be considered as confounding factors for this study.
Positive history of allergic reaction to "Anise", "Fennel", "Trachyspermum", "Caraway" and "Placebo composition"(Corn and wheat and barley).</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K30</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Functional dyspepsia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: This group receives the drug, which contains a traditional herbal composition. the components of the product include the seeds of the anise plant and the seeds of the fennel plant and the seeds of the Trachyspermum plant and the seeds of the caraway plant, which are grinded and placed in 8-gram sachets by traditional medicine pharmacist in the drug manufacturing center located in Emam Reza Clinic. Each patient is given 28 sachets. The method of taking the medicine is one sachet in the morning before breakfast and one sachet at night at bedtime, which is consumed with half a glass of water, and the treatment period is two weeks.</i_keyword>
      <i_keyword>Control group: The group that receives placebo. The placebo includes corn starch, wheat bran and barley flakes and 10% of the herbal composition of the drug (to simulate the appearance of the drug), which is prepared by a traditional medicine pharmacist in the drug manufacturing center located in Emam Reza Clinic in Shiraz and placed in 8 gram sachets.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Postprandial fullness. Timepoint: 2 weeks. Method of measurement: Gastrointestinal Symptoms Severity Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Epigastric pain&amp;burning sensation. Timepoint: 2 weeks. Method of measurement: Gastrointestinal Symptoms Severity Questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-01-17</approval_date>
        <contact_name>Research Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Zand Ave. Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
